摘要
目的探讨他汀类药物瑞舒伐他汀对合并轻度胆固醇升高的原发性高血压患者左心功能及动脉粥样硬化的影响。方法入选50～79岁原发性高血压伴心血管危险因素者79例,随机分分两组:他汀组40例及非他汀组39例,他汀组在使用氨氯地平+替米沙坦基础上加用瑞舒伐他汀(阿斯利康制药有限公司10～20mg/d,睡前),非他汀组在使用氨氯地平+替米沙坦基础上不用他汀类药物。入组时,两组患者低密度脂蛋白胆固醇(LDL-C)为2.6～3.6mmol/L。入组时和12个月后行超声心动图、核素心血池和64排螺旋CT冠状动脉钙化检查及测定血浆高敏C-反应蛋白(hs-CRP),比较治疗前后血浆hs-CRP、左室功能指数、冠状动脉钙化积分(LN)及颈动脉内膜中层厚度(IMT)。结果他汀组12月后,LDL-C较入组时下降33.2%,非他汀组较入组时无变化。他汀组12个月后,左室高峰充盈率(LVPFR)较入组时明显增加(P值<0.05);而高敏C-反应蛋白、LN及IMT显著下降(P值均<0.05)。结论对于轻度LDL-C升高的原发性高血压患者,常规降压药物基础上加用瑞舒伐他汀能明显改善左心室舒张功能及稳定或逆转动脉粥样硬化斑块。
Objective To observe the effect of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein （hs-CRP） in hypertensive patients with mild elevation of LDL-C. Methods Seventy-nine patients with a SBP of 140-179 mmHg and/or a DBP of 90-109 mmHg and mild elevated LDL-C were treated with rosuvastatin for 12 months （n=40） or not （n=39）. The changes of hs-CRP, arteriosclerosis plaque and cardiac function at the end of the 12-months treatment relative to the baseline levels were analyzed. Results After 12 months of treatment, LDL-C was decreased by 33.2% in rosuvastatin group but remained unchanged in patients without rosuvastatin treatment. The left ventricular peak filling rate （LVPFR） increased significantly from 1.85 to 2.59 （P0.05） and the serum levels of hs-CRP reduced significantly （P0.05） after rosuvastatin treatment. The size of the plaques reduced significantly after a 12-month rosuvastatin therapy. Conclusion Rosuvastatin therapy on the basis of conventional anti-hypertensive drugs can obviously improve the left ventricular diastolic function and produce favorable effects on arteriosclerotic plaques.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2010年第3期588-590,共3页
Journal of Southern Medical University
关键词
高血压
瑞舒伐他汀
高敏C-反应蛋白
左室功能指数
冠状动脉钙化积分
颈动脉内膜中层厚度
essential hypertension
rosuvastatin
C-reactive protein
left ventricular cardiac function index
arteriosclerosis
intima media thickness
common carotid artery
